Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00169988 · ClinicalTrials.gov registry record · NA
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
A NA study of Psychotic Disorders and Prodromal Schizophrenia, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00169988 is a NA study of Psychotic Disorders and Prodromal Schizophrenia that has completed, run by Northwell Health. The registered enrollment target is 8 participants, below the 255-participant average among 22 other Psychotic Disorders trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00169988, a NA study of Psychotic Disorders and Prodromal Schizophrenia, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts, suspiciousness and other unusual experiences, to improve reasoning ability, memory, attention and social skills in adolescents.
Conditions Studied
Interventions
- DRUG risperidone
- DRUG sertraline-primary
Study Locations (1)
New York
- RAP Program, Dept. of Psychiatry Research, The Zucker Hillside Hospital - Glen Oaks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-03 |
| Est. Completion | 2007-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00169988
The ClinicalTrials.gov registry entry for NCT00169988 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 22 other Psychotic Disorders trials with a reported enrollment target (97% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psychotic Disorders appearing as the primary indexed condition, and to 2 interventions - of which risperidone is the first listed.
NCT00169988 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00169988 about?
NCT00169988 is a clinical study titled "Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms". The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts, suspiciousness and other unusual experiences, to...
What is the current status of trial NCT00169988?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2004-03. Estimated completion is 2007-04.
What conditions does trial NCT00169988 study?
This clinical trial studies the following conditions: Psychotic Disorders, Prodromal Schizophrenia.
What interventions are being tested in trial NCT00169988?
The interventions under investigation include: risperidone (DRUG), sertraline-primary (DRUG).
Who is sponsoring clinical trial NCT00169988?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00169988 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychotic Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
-
A Preventive Behavioral Intervention for Young Adults With Psychotic Experiences
RECRUITING · NA
-
Racial Disparities in the Expression of Paranoia
RECRUITING · NA
-
Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders
RECRUITING · NA
-
A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness
RECRUITING · NA
-
CBT-CP for Veterans With SMI
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.